ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease. 

ESC 2021 | Novedades de las nuevas guías de valvulopatías de la Sociedad Europea de Cardiología

This new document was presented at the ESC 2021 Congress and simultaneously published in Eur Heart J.

These guidelines emphasize the importance of working as a team with surgeons to conduct personalized patient assessment.

This is the first time that clinical practice guidelines highly recommend involving patients in the decision-making process in gray areas, and having high-volume, specialized centers take on challenging cases.

Given the vast evidence on multiple procedures published, it no longer seems appropriate for referring cardiologists to refer patients directly to a surgeon or interventional cardiologist. The appropriate course of action would be referring the patient to a center specializing in valvular heart disease where the best team decision can be made (although this is far from what happens in daily clinical practice).

In aortic stenosis, age has come to play a leading role with class I recommendations.


Read also: ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate.


Surgery is recommended for patients <75 years old with low surgical risk or who are not candidates for transfemoral transcatheter aortic valve replacement (TAVR).

However, patients >75 years old or with high surgical risk (regardless of age) are candidates for TAVR.

For all other intermediate cases, both procedures are adequate, and the decision should be made according to the clinical, anatomical, and procedural characteristics discussed as a team and shared with the patient.


Read also: ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease.


Another important update is the recommendation to act early in aortic stenosis, aortic regurgitation, and mitral regurgitation.

2021-ESC_EACTS-Guidelines-for-the-management-of-valvular-heart-disease

Original Title: 2021 ESC/EACTS Guidelines for the management of valvular heart disease.

Reference: Alec Vahanian et al. Eur Heart J. 2021 Aug 28;ehab395. Online ahead of print. doi: 10.1093/eurheartj/ehab395. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

Balloon aortic valvuloplasty (BAV) has historically been used either as a bridge strategy, an assessment tool, or even palliative treatment in severe aortic stenosis...

TCT 2025 | SUMMIT-MAC: Transcatheter Mitral Valve Replacement with the Tendyne System in Patients with Severe Annular Calcification

The prospective, multicenter SUMMIT-MAC study evaluated the safety and efficacy of transcatheter mitral valve replacement (TMVR) using the Tendyne system in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...